JP2015509962A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015509962A5 JP2015509962A5 JP2014560093A JP2014560093A JP2015509962A5 JP 2015509962 A5 JP2015509962 A5 JP 2015509962A5 JP 2014560093 A JP2014560093 A JP 2014560093A JP 2014560093 A JP2014560093 A JP 2014560093A JP 2015509962 A5 JP2015509962 A5 JP 2015509962A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- clostridium difficile
- acid sequence
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 110
- 241000193163 Clostridioides difficile Species 0.000 claims description 88
- 239000000427 antigen Substances 0.000 claims description 67
- 108091007433 antigens Proteins 0.000 claims description 67
- 102000036639 antigens Human genes 0.000 claims description 67
- 239000012634 fragment Substances 0.000 claims description 66
- 208000024891 symptom Diseases 0.000 claims description 57
- 201000010099 disease Diseases 0.000 claims description 45
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 45
- 239000008194 pharmaceutical composition Substances 0.000 claims description 43
- 101710084578 Short neurotoxin 1 Proteins 0.000 claims description 35
- 101710182532 Toxin a Proteins 0.000 claims description 35
- 101710182223 Toxin B Proteins 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 201000011510 cancer Diseases 0.000 claims description 11
- 229940124597 therapeutic agent Drugs 0.000 claims description 11
- 210000000056 organ Anatomy 0.000 claims description 10
- 206010009657 Clostridium difficile colitis Diseases 0.000 claims description 9
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 8
- 108700022831 Clostridium difficile toxB Proteins 0.000 claims description 7
- 230000007774 longterm Effects 0.000 claims description 7
- 206010052779 Transplant rejections Diseases 0.000 claims description 6
- 108020003175 receptors Proteins 0.000 claims description 6
- 102000005962 receptors Human genes 0.000 claims description 6
- 208000037384 Clostridium Infections Diseases 0.000 claims description 5
- 206010054236 Clostridium difficile infection Diseases 0.000 claims description 5
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 5
- 206010061598 Immunodeficiency Diseases 0.000 claims description 5
- 239000003242 anti bacterial agent Substances 0.000 claims description 5
- 229940088710 antibiotic agent Drugs 0.000 claims description 5
- 230000001506 immunosuppresive effect Effects 0.000 claims description 5
- 239000003112 inhibitor Substances 0.000 claims description 5
- 229940126409 proton pump inhibitor Drugs 0.000 claims description 5
- 239000000612 proton pump inhibitor Substances 0.000 claims description 5
- 102100021324 5-azacytidine-induced protein 2 Human genes 0.000 claims description 4
- 208000004998 Abdominal Pain Diseases 0.000 claims description 4
- 206010000060 Abdominal distension Diseases 0.000 claims description 4
- 208000005156 Dehydration Diseases 0.000 claims description 4
- 206010012735 Diarrhoea Diseases 0.000 claims description 4
- 208000032843 Hemorrhage Diseases 0.000 claims description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims description 4
- 108090001007 Interleukin-8 Proteins 0.000 claims description 4
- 208000002720 Malnutrition Diseases 0.000 claims description 4
- 208000003100 Pseudomembranous Enterocolitis Diseases 0.000 claims description 4
- 206010037128 Pseudomembranous colitis Diseases 0.000 claims description 4
- 206010037660 Pyrexia Diseases 0.000 claims description 4
- 206010040047 Sepsis Diseases 0.000 claims description 4
- 208000022531 anorexia Diseases 0.000 claims description 4
- 208000034158 bleeding Diseases 0.000 claims description 4
- 230000000740 bleeding effect Effects 0.000 claims description 4
- 238000012321 colectomy Methods 0.000 claims description 4
- 206010061428 decreased appetite Diseases 0.000 claims description 4
- 230000018044 dehydration Effects 0.000 claims description 4
- 238000006297 dehydration reaction Methods 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 4
- 230000002496 gastric effect Effects 0.000 claims description 4
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 230000001071 malnutrition Effects 0.000 claims description 4
- 235000000824 malnutrition Nutrition 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 208000015380 nutritional deficiency disease Diseases 0.000 claims description 4
- 230000009885 systemic effect Effects 0.000 claims description 4
- 230000001668 ameliorated effect Effects 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 229940041181 antineoplastic drug Drugs 0.000 claims description 3
- 230000003115 biocidal effect Effects 0.000 claims description 3
- 239000003018 immunosuppressive agent Substances 0.000 claims description 3
- 229940124589 immunosuppressive drug Drugs 0.000 claims description 3
- 238000009116 palliative therapy Methods 0.000 claims description 3
- 238000001959 radiotherapy Methods 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 229960005486 vaccine Drugs 0.000 claims description 3
- 206010017943 Gastrointestinal conditions Diseases 0.000 claims description 2
- 101150056637 Hrh2 gene Proteins 0.000 claims description 2
- 206010022714 Intestinal ulcer Diseases 0.000 claims description 2
- 125000000539 amino acid group Chemical group 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 201000006549 dyspepsia Diseases 0.000 claims description 2
- 208000024798 heartburn Diseases 0.000 claims description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 2
- 229960001340 histamine Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 239000003053 toxin Substances 0.000 claims description 2
- 231100000765 toxin Toxicity 0.000 claims description 2
- 108700012359 toxins Proteins 0.000 claims description 2
- 241000193403 Clostridium Species 0.000 claims 1
- 230000002554 disease preventive effect Effects 0.000 claims 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 4
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261605914P | 2012-03-02 | 2012-03-02 | |
| US61/605,914 | 2012-03-02 | ||
| US201261608255P | 2012-03-08 | 2012-03-08 | |
| US61/608,255 | 2012-03-08 | ||
| US201261717404P | 2012-10-23 | 2012-10-23 | |
| US61/717,404 | 2012-10-23 | ||
| PCT/US2013/028630 WO2013130981A1 (en) | 2012-03-02 | 2013-03-01 | Human antibodies to clostridium difficile toxins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017231934A Division JP2018029625A (ja) | 2012-03-02 | 2017-12-01 | Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ毒素に対するヒト抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015509962A JP2015509962A (ja) | 2015-04-02 |
| JP2015509962A5 true JP2015509962A5 (enExample) | 2016-04-07 |
Family
ID=47844536
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014560093A Pending JP2015509962A (ja) | 2012-03-02 | 2013-03-01 | Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ毒素に対するヒト抗体 |
| JP2017231934A Pending JP2018029625A (ja) | 2012-03-02 | 2017-12-01 | Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ毒素に対するヒト抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017231934A Pending JP2018029625A (ja) | 2012-03-02 | 2017-12-01 | Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ毒素に対するヒト抗体 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US9399674B2 (enExample) |
| EP (1) | EP2820044A1 (enExample) |
| JP (2) | JP2015509962A (enExample) |
| KR (1) | KR20140130709A (enExample) |
| CN (2) | CN104203976A (enExample) |
| AR (1) | AR090219A1 (enExample) |
| AU (1) | AU2016203511A1 (enExample) |
| BR (1) | BR112014021251A2 (enExample) |
| CA (1) | CA2863536A1 (enExample) |
| HK (1) | HK1200463A1 (enExample) |
| IL (1) | IL233884A0 (enExample) |
| MX (1) | MX2014010527A (enExample) |
| NZ (2) | NZ628943A (enExample) |
| RU (2) | RU2628305C2 (enExample) |
| SG (2) | SG11201405087PA (enExample) |
| TW (1) | TWI592422B (enExample) |
| UY (1) | UY34652A (enExample) |
| WO (1) | WO2013130981A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3028565B1 (en) | 2009-07-08 | 2017-09-27 | Kymab Limited | Animal models and therapeutic molecules |
| EP2757875B2 (en) | 2011-09-19 | 2023-03-22 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
| US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
| US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
| GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
| US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
| US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
| US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
| US9181632B1 (en) | 2013-09-09 | 2015-11-10 | Merck Sharp & Dohme Corp. | C.difficile toxin B CROP domain peptides, antibodies and complexes thereof |
| WO2015049517A2 (en) | 2013-10-01 | 2015-04-09 | Kymab Limited | Animal models and therapeutic molecules |
| ES2870506T3 (es) | 2015-02-19 | 2021-10-27 | Immune Biosolutions Inc | Antígeno y anticuerpo del epítopo de las toxinas a y/o b de clostridium difficile, y sus usos farmacéuticos |
| JP2018517670A (ja) * | 2015-04-15 | 2018-07-05 | メディミューン，エルエルシー | クロストリジウム・ディフィシル（Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ）感染および関連疾患の治療方法 |
| EP3445783A2 (en) | 2016-04-18 | 2019-02-27 | Celldex Therapeutics, Inc. | Agonistic antibodies that bind human cd40 and uses thereof |
| WO2017189964A2 (en) * | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| EP3753952A4 (en) * | 2017-12-13 | 2022-04-13 | XDCExplorer (Shanghai) Co., Ltd. | EGFRVIII ANTIBODY AND CONJUGATE, AND METHODS FOR ITS PRODUCTION AND USE |
| WO2020060771A1 (en) * | 2018-09-18 | 2020-03-26 | Vanderbilt University | Human monoclonal antibodies to staphylococcal aureus isd proteins and uses thereof |
| US20200148762A1 (en) * | 2018-11-09 | 2020-05-14 | Avamab Pharma Inc. | Methods for regulating endogenous production of antibodies against infectious diseases |
| CN111793130B (zh) * | 2019-03-20 | 2021-09-14 | 华中农业大学 | 一株副猪嗜血杆菌CdtB杂交瘤细胞及单克隆抗体应用 |
| KR102376876B1 (ko) | 2020-04-09 | 2022-03-21 | 대진대학교 산학협력단 | 무독성의 클로스트리디움 디피실 독소단백질-단편 및 이의 용도 |
| WO2021219786A1 (en) | 2020-04-30 | 2021-11-04 | Gottfried Himmler | Anti-toxin secretory iga2 preparation |
| WO2025029561A2 (en) * | 2023-07-28 | 2025-02-06 | University Of South Florida | Vaccine containing rbd2 of cdtb component from binary toxin cdt of clostridioides difficile |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4879218A (en) | 1982-09-13 | 1989-11-07 | Virginia Tech Intellectual Properties, Inc. | Antibody for C.difficile |
| US5358868A (en) | 1987-11-24 | 1994-10-25 | Connaught Laboratories Limited | Genetic detoxification of pertussis toxin |
| GB8727489D0 (en) | 1987-11-24 | 1987-12-23 | Connaught Lab | Detoxification of pertussis toxin |
| US5221618A (en) | 1987-11-24 | 1993-06-22 | Connaught Laboratories Limited | Genetic detoxification of pertussis toxin |
| US5332583A (en) | 1987-11-24 | 1994-07-26 | Connaught Laboratories Limited | Vaccine containing genetically-detoxified pertussis holotoxin |
| US5244657A (en) | 1987-11-24 | 1993-09-14 | Connaught Laboratories Limited | Genetic detoxification of pertussis toxin |
| US5224657A (en) | 1989-05-23 | 1993-07-06 | Kabushiki Kaisha Toshiba | Cryogenic refrigerator |
| US5231003A (en) | 1990-05-11 | 1993-07-27 | Cambridge Bioscience Corporation | Monoclonal antibodies specific for toxin b of clostridium difficile |
| JP4312259B2 (ja) * | 1995-04-27 | 2009-08-12 | アムジェン フレモント インク． | 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体 |
| DE19739685A1 (de) * | 1997-09-10 | 1999-03-11 | Eichel Streiber Christoph Von | Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile |
| DE69829400T2 (de) | 1997-10-20 | 2006-04-13 | Acambis, Inc., Cambridge | Passive immunisierung gegen durch clostridium difficile verursachte krankheit |
| EP1568378B1 (en) | 1997-10-20 | 2016-03-16 | Sanofi Pasteur Biologics, LLC | Immunization against Clostridium difficile disease |
| US6969520B2 (en) | 1997-10-20 | 2005-11-29 | Acambis Inc. | Active immunization against clostridium difficile disease |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| GB0309126D0 (en) | 2003-04-17 | 2003-05-28 | Neutec Pharma Plc | Clostridium difficile focussed antibodies |
| CN1809591A (zh) * | 2003-05-21 | 2006-07-26 | 米德列斯公司 | 针对炭疽芽孢杆菌保护性抗原的人单克隆抗体 |
| DK1766093T3 (da) * | 2004-02-06 | 2011-10-03 | Univ Massachusetts | Antistoffer mod clostridium difficile-toksiner og anvendelse deraf |
| EP1740946B1 (en) | 2004-04-20 | 2013-11-06 | Genmab A/S | Human monoclonal antibodies against cd20 |
| EP1833510A4 (en) | 2004-12-27 | 2010-02-10 | Progenics Pharmaceuticals Neva | ORAL ADMINISTRATION ANTITOXIN ANTIBODIES AND METHODS OF MAKING AND USING THE SAME |
| UA109105C2 (uk) * | 2006-04-17 | 2015-07-27 | Молекула нуклеїнової кислоти, що кодує істотно нетоксичний мутеїн альфа-токсину clostridium perfringens, та істотно нетоксичний мутеїн альфа-токсину clostridium perfringens | |
| CA2652976C (en) | 2006-06-02 | 2015-08-11 | Regeneron Pharmaceuticals, Inc. | High affinity antibodies to human il-6 receptor |
| UA96768C2 (uk) * | 2006-08-02 | 2011-12-12 | Йоганес Гутенберг-Універсітет Майнц | Лікарський засіб від lct-отруєнь |
| US8084684B2 (en) | 2006-10-09 | 2011-12-27 | Solexel, Inc. | Three-dimensional thin-film solar cells |
| US20110020356A1 (en) | 2007-12-07 | 2011-01-27 | Lin Fang | Therapeutic clostridium difficile antibody compositions |
| CA2714720A1 (en) | 2008-02-28 | 2009-09-03 | 3M Innovative Properties Company | Antibodies to clostridium difficile spores and uses thereof |
| WO2010094970A1 (en) | 2009-02-20 | 2010-08-26 | Health Protection Agency | Antibodies to clostridium difficile toxins |
| MX368932B (es) | 2009-06-26 | 2019-10-22 | Regeneron Pharma | Anticuerpos biespecificos facilmente aislados con formato de inmunoglobulina original. |
| PL2480255T3 (pl) * | 2009-09-23 | 2018-07-31 | Thomas Julius Borody | Terapia przewlekłych zakażeń jelitowych |
| WO2011063346A1 (en) | 2009-11-20 | 2011-05-26 | Northshore University Health System Research Institute | Targeting of the c-terminal segment of c. difficile toxin b for improved clinical diagnosis, prevention, and treatment |
| SMT201900372T1 (it) | 2010-02-08 | 2019-09-09 | Regeneron Pharma | Topo con catena leggera comune |
| JP5965389B2 (ja) * | 2010-04-15 | 2016-08-03 | プロゲニクス ファーマシューティカルズ インコーポレーテッドＰｒｏｇｅｎｉｃｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | クロストリジウム・ディフィシル関連感染症および疾患を治療するための抗体 |
-
2013
- 2013-03-01 RU RU2014139552A patent/RU2628305C2/ru not_active IP Right Cessation
- 2013-03-01 JP JP2014560093A patent/JP2015509962A/ja active Pending
- 2013-03-01 SG SG11201405087PA patent/SG11201405087PA/en unknown
- 2013-03-01 EP EP13708641.9A patent/EP2820044A1/en not_active Withdrawn
- 2013-03-01 UY UY0001034652A patent/UY34652A/es unknown
- 2013-03-01 WO PCT/US2013/028630 patent/WO2013130981A1/en not_active Ceased
- 2013-03-01 HK HK15100241.0A patent/HK1200463A1/xx unknown
- 2013-03-01 TW TW102107190A patent/TWI592422B/zh not_active IP Right Cessation
- 2013-03-01 CN CN201380012035.0A patent/CN104203976A/zh active Pending
- 2013-03-01 BR BR112014021251A patent/BR112014021251A2/pt not_active IP Right Cessation
- 2013-03-01 SG SG10201610123UA patent/SG10201610123UA/en unknown
- 2013-03-01 KR KR1020147026227A patent/KR20140130709A/ko not_active Withdrawn
- 2013-03-01 NZ NZ628943A patent/NZ628943A/en not_active IP Right Cessation
- 2013-03-01 RU RU2017127772A patent/RU2017127772A/ru not_active Application Discontinuation
- 2013-03-01 AR ARP130100670A patent/AR090219A1/es unknown
- 2013-03-01 CA CA2863536A patent/CA2863536A1/en not_active Abandoned
- 2013-03-01 MX MX2014010527A patent/MX2014010527A/es unknown
- 2013-03-01 CN CN201711446090.7A patent/CN108101983A/zh active Pending
- 2013-03-01 NZ NZ714516A patent/NZ714516A/en not_active IP Right Cessation
- 2013-03-01 US US13/782,444 patent/US9399674B2/en active Active
-
2014
- 2014-07-30 IL IL233884A patent/IL233884A0/en unknown
-
2016
- 2016-05-27 AU AU2016203511A patent/AU2016203511A1/en not_active Abandoned
- 2016-06-01 US US15/170,602 patent/US20160264650A1/en not_active Abandoned
-
2017
- 2017-12-01 JP JP2017231934A patent/JP2018029625A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015509962A5 (enExample) | ||
| RU2014139552A (ru) | Человеческие антитела к токсинам clostridium difficile | |
| CN111511765B (zh) | 抗半乳凝素-9抗体及其用途 | |
| JP7458453B2 (ja) | Ｂｅｔ ｖ １に対するヒト抗体およびその使用方法 | |
| EP3950716A1 (en) | Anti-claudin 18.2 antibody and application thereof | |
| JP2020536109A5 (enExample) | ||
| CN109563170B (zh) | 抗gitr抗体及其用途 | |
| JP2020500003A5 (enExample) | ||
| JP2020504171A (ja) | 抗ＰＤ−１抗体との組み合わせのための抗Ｔｉｍ−３抗体 | |
| RU2014148502A (ru) | Человеческие антитела к fel d1 и способы их применения | |
| CA2786479A1 (en) | Methods for treating pancreatic cancer | |
| AU2018348429A1 (en) | Multispecific antibody | |
| TW201219568A (en) | Antibody targeting osteoclast-related protein Siglec-15 | |
| JP2014534806A5 (enExample) | ||
| BR112012026021A2 (pt) | anticorpos monoclonais e biespecífico, seus fragmentos de ligação ao antígeno e proteína de ligação para o tratamento de infecção e doença associadas ao clostridium difficile, bem como composição, vacina ou agente imunogênico, linhagem de células de hibridoma, ácido nucleico, processo de produção dos referidos anticorpos, kit, vetor de expressão, método ex vivo e usos | |
| JP2013523190A5 (enExample) | ||
| JP2015503909A5 (enExample) | ||
| TW202311284A (zh) | 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體 | |
| KR20240052084A (ko) | 조합 및 이의 용도 | |
| WO2023040940A1 (zh) | Pvrig/tigit结合蛋白联合免疫检查点抑制剂用于治疗癌症 | |
| BR112019020812A2 (pt) | anticorpos anti-pd-l1-anti-tim-3 biespecíficos | |
| WO2020143749A1 (zh) | 重组抗人pd-1抗体及其应用 | |
| CA2982358A1 (en) | Methods for treating clostridium difficile infection and associated disease | |
| JP2021531263A (ja) | 抗ヒトｐｄ−ｌ１抗体とその使用 | |
| JP7643727B2 (ja) | 抗－ｆｇｆ１９抗体 |